CC BY-NC-ND 4.0 · South Asian J Cancer 2019; 08(01): 40-51
DOI: 10.4103/sajc.sajc_287_18
Letter to the Editor

Chronic lymphocytic leukemia with deletion 17p: An Indian scenario

Ajay Gogia
Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi
,
Ritu Gupta
Department of Lab Oncology, All India Institute of Medical Sciences, New Delhi
,
Lalit Kumar
Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi
,
Atul Sharma
Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi
,
Lata Soni
Department of Lab Oncology, All India Institute of Medical Sciences, New Delhi
› Author Affiliations
Financial support and sponsorship: Nil.


Publication History

Publication Date:
21 December 2020 (online)

© 2019. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 
  • References

  • 1 Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-6.
  • 2 Zenz T, Gribben JG, Hallek M, Döhner H, Keating MJ, Stilgenbauer S, et al. Risk categories and refractory CLL in the era of chemoimmunotherapy. Blood 2012;119:4101-7.
  • 3 Strati P, Keating MJ, O'Brien SM, Ferrajoli A, Burger J, Faderl S, et al. Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. Haematologica 2014;99:1350-5.
  • 4 Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the international workshop on chronic lymphocytic leukemia updating the national cancer institute-working group 1996 guidelines. Blood 2008;111:5446-56.
  • 5 Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219-34.
  • 6 Rani L, Mathur N, Gogia A, Vishnubhatla S, Kumar L, Sharma A, et al. Immunoglobulin heavy chain variable region gene repertoire and B-cell receptor stereotypes in Indian patients with chronic lymphocytic leukemia. Leuk Lymphoma 2016;57:2389-400.
  • 7 Fischer K, Cramer P, Busch R, Böttcher S, Bahlo J, Schubert J, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: A multicenter phase II trial of the German chronic lymphocytic leukemia study group. J Clin Oncol 2012;30:3209-16.
  • 8 Gogia A, Sharma A, Raina V, Kumar L, Vishnubhatla S, Gupta R, et al. Assessment of 285 cases of chronic lymphocytic leukemia seen at single large tertiary center in Northern India. Leuk Lymphoma 2012;53:1961-5.